| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 338-AC-010/CF | |||
| Carrier Free | 338-AC-050/CF | |||
| Carrier Free | 338-AC-01M/CF | |||
| Carrier Free | 338-AC-500/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 338-AC-050/CF | |||
| Carrier Free | 338-AC-01M/CF | |||
| Carrier Free | 338-AC-500/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF338-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3381-SP | |||
| Carrier Free | MAB3381-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-43663-25ul | |||
| Azide and BSA Free | NBP3-44161 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | Qk005-0500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | BT-ACTAH-010 | |||
| Carrier Free | BT-ACTAH-050 | |||
| Carrier Free | BT-ACTAH-500 | |||
| Carrier Free | BT-ACTAH-01M | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | Qk035-0500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 11348-AC-020 | |||
| Carrier Free | 11348-AC-050 | |||
| Carrier Free | 11348-AC-500 | |||
| Carrier Free | 11348-AC-01M | |||
![N/A Activin A [HRP]](http://images.novusbio.com/fullsize2/DATA_Activin_A_DAC00_ELISA_561.jpg "N/A Activin A [HRP]")
![N/A Activin A [HRP]](http://images.novusbio.com/fullsize2/Activin_A_DAC00_ELISA_381.jpg)
![N/A Activin A [Biotin]](http://images.novusbio.com/fullsize2/DATA_Activin_A_DY338_ELISA_1940.jpg "N/A Activin A [Biotin]")
![Western Blot: Activin A Antibody [NBP1-30928] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Inhibin beta A antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Activin-A-Antibody-Western-Blot-NBP1-30928-img0009.jpg "Western Blot: Activin A Antibody [NBP1-30928] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Inhibin beta A antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![Immunocytochemistry/Immunofluorescence: Activin A Antibody [NBP1-30928] - Paraformaldehyde-fixed HeLa, using antibody at 1:200 dilution.](http://images.novusbio.com/fullsize/Inhibin-beta-A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-30928-img0003.jpg)
![Immunohistochemistry-Paraffin: Activin A Antibody [NBP1-30928] - CLEAR CELL OVCA xenograft, using Inhibin beta A antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/Inhibin-beta-A-Antibody-Immunohistochemistry-Paraffin-NBP1-30928-img0004.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Activin A Antibody [NBP1-30928] - Western blot analyses of YY1 and inhibin betaA in MDA-231 cells co-transfected with miR-218 mimic and YY1-overexpressing plasmid, or the corresponding controls at 72 h. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-1059-y), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Activin-A-Antibody-Western-Blot-NBP1-30928-img0007.jpg)
![Western Blot: Activin A Antibody [NBP1-30928] - miR-218 directly targets INHBB & YY1, & increases INHBA expression. a Relative RNA level of INHBB & INHBA normalized to 18S in MDA-231 transfected with miR-218 or control miRNA mimic at 24 h & 72 h, respectively. ***P < 0.001. b Western blot analyses of inhibin beta B & inhibin beta A in mimic-transfected MDA-231 cells at 48 h. c Relative RNA level of INHBB & INHBA normalized to 18S in MDA-231-bone transfected with anti-miR-218 or control antagomiR at 24 h & 48 h, respectively.. **P < 0.01; ***P < 0.001. d Sequence alignment of miR-218 & its predicted targets INHBB & YY1. e psiCheck2 reporter plasmids & miR-218 mimic or its corresponding control were transfected into indicated cell lines. Renilla & firefly luciferase activity was measured at 48 h. *P < 0.05; n.s. not significant. f Relative RNA level of YY1 normalized to 18S in mimic-transfected MDA-231 cells at 24 h. ***P < 0.001. g Western blot analyses of YY1 & inhibin beta A in MDA-231 cells co-transfected with miR-218 mimic & YY1-overexpressing plasmid, or the corresponding controls at 72 h. h psiCheck2 reporter plasmids & miR-218 mimic or its corresponding control vector were transfected into MDA-231 cells. Renilla & firefly luciferase activity was measured at 48 h. **P < 0.01; n.s. not significant Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30348200), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-30928_rabbit-polyclonal-activin-a-antibody-310202416175215.jpg)
![Western Blot: Activin A Antibody [NBP1-30928] - miR-218-regulated inhibin beta A affects SMAD2/3 signaling in a cell-dependent manner. a & b Western blot analyses of phospho-SMAD2/3 in MDA-231 (a) or MC3T3 (b) that was serum-starved overnight & treated with EV-depleted CM collected from indicated cells for 30 min or 2 h. CM producing cell lines were transfected, PBS washed 48 h after transfection & then incubated with serum-free medium overnight before CM collection & EV depletion by ultracentrifugation. c Western blot analyses of inhibin beta A, inhibin beta B, & inhibin alpha in CM from indicated cell lines that was concentrated with medium concentrator columns. Arrows indicate the position of antigen. Control mimic-transfected MDA-231 whole cell lysate (WCL) was used as positive control for inhibin beta A & inhibin beta B. d Western blot analyses of inhibin beta A monomer or dimer (activin A) in CM from indicated cell lines under non-reducing condition & without boiling the samples. Bottom & top arrows indicate inhibin beta A monomer & dimer, respectively. e Western blot analyses of inhibin alpha in MC3T3 CM concentrated from 20 ml CM. WCL of MCF10A was used as a positive control. f & g Western blot analyses of phospho-SMAD2/3 in MDA-231 (f) or MC3T3 (g) that was serum-starved overnight & treated with CM collected from indicated cells for 30 min or 2 h. For MDA-231 cells (f), recombinant inhibin alpha protein was added to CM as indicated. For MC3T3 cells (g), anti-inhibin alpha antibody was added to CM as indicated Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30348200), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-30928_rabbit-polyclonal-activin-a-antibody-310202416171458.jpg)
![Western Blot: Activin A Antibody [NBP1-30928] - PC-3 conditioned medium (30 μg) was separated by 10% SDS-PAGE, and the membrane was blotted with Inhibin beta A antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/antibody/nbp1-30928_rabbit-polyclonal-activin-a-antibody-western-blot-612202495750..png)
